T 1744/14 of 22.11.2019

European Case Law Identifier: ECLI:EP:BA:2019:T174414.20191122
Date of decision: 22 November 2019
Case number: T 1744/14
Petition for review of: -
Application number: 04015299.3
IPC class: A61P 7/02 A61K 31/519 A61P 9/10 C07D 487/04
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: New crystalline and amorphous form of a triazolo(4,5-D)pyrimidine compound
Applicant name: AstraZeneca AB
Opponent name: Hexal AG
Board: 3.3.02
Headnote: -
Relevant legal provisions: European Patent Convention Art 123(2)European Patent Convention Art 54(3)European Patent Convention Art 56 European Patent Convention Art 83 European Patent Convention Art 87(1)Rules of procedure of the Boards of Appeal Art 12(2)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(3)
Keywords: Novelty - (yes)
Priority - basis in priority document (yes)
Catchword: -
Cited cases: T 0777/08 T 0593/09 T 2001/12 T 1845/14 T 1311/15
Citing cases: T 0500/16 T 2117/18 T 0114/19 T 0460/19 T 0724/20

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division with the order to maintain the patent with the following claims and a description to be adapted thereto:

claims 1 to 14 of the main request, filed with the statements of grounds of appeal.